Lantheus Holdings, Inc. (NASDAQ:LNTH) Short Interest Down 13.3% in February

Lantheus Holdings, Inc. (NASDAQ:LNTH) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 6,340,000 shares, a drop of 13.3% from the February 13th total of 7,310,000 shares. Approximately 9.5% of the shares of the stock are sold short. Based on an average daily volume of 902,000 shares, the days-to-cover ratio is currently 7.0 days.

Lantheus Stock Performance

NASDAQ:LNTH traded up $0.17 during mid-day trading on Wednesday, reaching $102.39. The stock had a trading volume of 91,070 shares, compared to its average volume of 935,511. The firm has a market capitalization of $7.01 billion, a price-to-earnings ratio of 17.03 and a beta of 0.38. Lantheus has a twelve month low of $56.52 and a twelve month high of $126.89. The business has a 50 day simple moving average of $92.35 and a 200 day simple moving average of $96.64.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts expect that Lantheus will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,109 shares of company stock valued at $5,105,606 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Lantheus

Several institutional investors have recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the 3rd quarter valued at $25,000. Kestra Investment Management LLC acquired a new position in shares of Lantheus during the 4th quarter valued at $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus during the 4th quarter valued at $37,000. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus during the 3rd quarter valued at $60,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on LNTH shares. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial increased their target price on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.